You are here: Industry Insights > Takeda

News List

Emendo Biotherapeutics Achieves Collaboration Milestone with Takeda americanpharmaceuticalreview
August 22, 2019
Emendo Biotherapeutics has announced that the company achieved the first milestone as laid out in the agreements with Takeda Pharmaceutical Company Limited (Takeda) ...
Takeda Ireland Implements Werum’s PAS-X MES contractpharma
August 21, 2019
Werum’s PAS-X MES automatically pulls manufacturing data from the shop floor by integrating Takeda’s Process Control System.
Emendo Biotherapeutics Achieves Takeda Milestone contractpharma
August 21, 2019
Funds will be used to further advance Emendo's nuclease discovery platform and portfolio development programs.
Does Stada need Takeda's for-sale European drugs? CEO says no fiercepharma
August 15, 2019
If German generics maker Stada is looking for a large deal, Takeda’s reportedly for-sale European drugs could be a good target. But to hear Stada's CEO tell it, the company has plenty of choices.
Takeda staffers accuse drugmaker of favoring Shire employees during merger fiercepharma
August 13, 2019
During a merger, one might suspect a buyer could favor its old employees over the newcomers. But that’s not what's happened at Takeda Korea as it folds in Shire, according to a labor union.
Takeda, Sosei form gastrointestinal disease R&D pact fiercepharma
August 13, 2019
Takeda and Sosei Heptares have entered into a multitarget R&D agreement. Sosei is set to receive $26 million (€23 million) in upfront and near-term payments, plus up to $1.2 billion in milestones, to apply its GPCR expertise to targets of interest to Take
Takeda submits NDA for SC formation of ulcerative colitis treatment pharmaceutical-technology
August 09, 2019
Takeda Pharmaceutical has submitted a new drug application (NDA) in Japan for a subcutaneous (SC) formulation of vedolizumab to treat adults with moderately to severely active ulcerative colitis (UC).
Kamada, Takeda Discuss GLASSIA Manufacturing Transition contractpharma
August 09, 2019
In discussions to extend transition of Kamada’s Alpha-1 Antitrypsin Deficiency treatment to Takeda.
Sosei Group and Takeda to develop and commercialise new drug molecules pharmaceutical-technology
August 07, 2019
Sosei Group’s wholly-owned subsidiary Heptares Therapeutics and Takeda Pharmaceutical have signed an agreement to discover, develop and commercialise new molecules, including small molecules and biologics.
Sosei Heptares, Takeda Announce Partnership americanpharmaceuticalreview
August 07, 2019
Sosei Heptares has entered into a strategic multi-target partnership with Takeda Pharmaceutical to discover, develop and commercialize novel molecules, including small molecules and biologics that modulate G protein-coupled receptor (GPCR) targets.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page